Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 2,883 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard of Care Alone Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection

NCT00606086
View directory record Official record
Conditions
Genotype 1 Chronic Hepatitis C
Interventions
GI-5005, Pegylated Interferon and Ribavirin
Drug
Lead sponsor
GlobeImmune
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
25
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 19, 2026, 4:21 PM EDT
Completed Phase 1 Interventional

hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

NCT02960594
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Pancreatic Cancer, Head and Neck Cancer, Ovarian Cancer, ColoRectal Cancer, Gastric Cancer, Esophageal Cancer, HepatoCellular Carcinoma
Interventions
INO-1400, INO-9012, INO-1401
Biological
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Detroit, Michigan • Rochester, Minnesota • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 19, 2026, 4:21 PM EDT
Completed Phase 2 Interventional

Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy

NCT00120861
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
valopicitabine, pegylated interferon, ribavirin
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Timeline
Started 2005
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Oct 19, 2026, 4:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of the Refugee Family Strengthening (RFS) Program

NCT02829086
View directory record Official record
Conditions
Health Behavior
Interventions
Relationship Enhancement, Family Stress and Conflict Management, Financial Management
Other
Lead sponsor
US Committee for Refugees and Immigrants
Other
Eligibility
16 Years and older
Enrollment
5,365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
11
States / cities
Los Angeles, California • Des Moines, Iowa • Dearborn, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Oct 19, 2026, 4:21 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

NCT06251973
View directory record Official record
Conditions
Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastric Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Cancer, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastric Carcinoma, Unresectable Esophageal Cancer, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Carcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Interventions
AgenT-797, Botensilimab, Balstilimab, Ramucirumab, Paclitaxel
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 19, 2026, 4:21 PM EDT
Recruiting Phase 4 Interventional

Multi-Center PAMPA Study

NCT05004727
View directory record Official record
Conditions
Psoriasis
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 19, 2026, 4:21 PM EDT
Completed Early Phase 1 Interventional

Utility of ICG in Benign Bone Tumors

NCT05075889
View directory record Official record
Conditions
Bone Tumor
Interventions
Indocyanine Green
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
12 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 19, 2026, 4:21 PM EDT
Recruiting Phase 1Phase 2 Interventional

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

NCT06814496
View directory record Official record
Conditions
Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma, Esthesioneuroblastoma, Bladder Cancer, Testicular Cancer, Glioblastoma Multiforme, Cervical Cancer, Large Cell Neuroendocrine Carcinoma of the Lung, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
Interventions
Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy
Drug · Radiation
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Gilbert, Arizona • Tucson, Arizona • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 4:21 PM EDT
Completed Not applicable Interventional Results available

Assessment of an Endotracheal Tube Securement Device

NCT01651260
View directory record Official record
Conditions
Respiratory Insufficiency
Interventions
Experimental ET Tube Securement Device
Other
Lead sponsor
Hollister Incorporated
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Hartford, Connecticut • Washington D.C., District of Columbia • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 19, 2026, 4:21 PM EDT
Completed No phase listed Observational

A Pilot, Randomized Controlled Trial of Group Visits for Persons With Parkinson's Disease

NCT00528086
View directory record Official record
Conditions
Parkinson's Disease, Parkinson's Disease Patient Caregivers
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
30 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2010 · Synced Oct 19, 2026, 4:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

SZMN Blocks for Pain Control in Pediatric Patients Undergoing T&A

NCT04797559
View directory record Official record
Conditions
Postoperative Pain, Opioid Use
Interventions
SZMN Block
Procedure
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 18 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 19, 2026, 4:21 PM EDT
Terminated Not applicable Interventional

Registry-based HCV Care Cascade Navigation at Atlanta's Grady Memorial Hospital

NCT03441542
View directory record Official record
Conditions
Hepatitis C
Interventions
Data-assisted Case Navigation, Standard of Care
Behavioral
Lead sponsor
National Opinion Research Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 19, 2026, 4:21 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients

NCT06353997
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Pembrolizumab, INBRX-106
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Los Angeles, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 19, 2026, 4:21 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The STOP-HPV Trial 5: Single Arm Evaluation of the Bundle

NCT03609320
View directory record Official record
Conditions
Immunization, Vaccination
Interventions
The STOP-HPV Trial 5: Bundle Intervention
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
11 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Itasca, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 19, 2026, 4:21 PM EDT
Completed No phase listed Observational Results available

Evaluating Cancer Survivorship Care Models

NCT02362750
View directory record Official record
Conditions
Quality of Life, Cancer
Interventions
Consultative Specialized Survivorship Clinic (CSSC), Longitudinal Specialized Survivorship Clinic (LSSC), Oncology Embedded Survivorship Clinic (OESC)
Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
991 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 19, 2026, 4:21 PM EDT
Terminated Phase 3 Interventional

Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer

NCT00254891
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
PF-3512676 + Paclitaxel + Carboplatin, Paclitaxel + Carboplatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
89
States / cities
Little Rock, Alaska • Hot Springs, Arkansas • Chula Vista, California + 69 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 19, 2026, 4:21 PM EDT
Recruiting Phase 3 Interventional

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

NCT07611110
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]), Cabazitaxel, Abiraterone, Enzalutamide, Apalutamide, Darolutamide, Deutenzalutamide, Radium-223
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
28
States / cities
Dothan, Alabama • Phoenix, Arizona • Duarte, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 19, 2026, 4:21 PM EDT
Completed Not applicable Interventional

Point-of-Care Adipose-derived Cells for Hair Growth

NCT02729415
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
Stromal Vascular Fraction Cells (SVF Cells) Injection, Liposuction, Hair Measurements
Procedure · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Oct 19, 2026, 4:21 PM EDT
Completed Phase 4 Interventional Results available

Internet Surveys and Their Impact on Adherence for Rosacea

NCT03048058
View directory record Official record
Conditions
Rosacea
Interventions
brimonidine topical gel 0.33% & survey, brimonidine topical gel 0.33% & SOC
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 19, 2026, 4:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pre-exposure Prophylaxis (PrEP) at Home

NCT03569813
View directory record Official record
Conditions
HIV/AIDS
Interventions
PrEP@Home System, Standard of Care
Behavioral · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
318 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Jackson, Mississippi + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 19, 2026, 4:21 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Conformal Ablative Radiotherapy in Older Women (CARMEN) With Breast Cancer Undergoing Non-Operative Management

NCT07242118
View directory record Official record
Conditions
Breast Cancer Female
Interventions
SABR
Radiation
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
65 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 19, 2026, 4:21 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

KULEA-NET: A Mobile Application for African American/Black Mothers to Promote Exclusive and Continuous Breastfeeding

NCT05985876
View directory record Official record
Conditions
Breastfeeding, Exclusive Breastfeeding
Interventions
KULEA-NET application, Control Group: Usual Care
Behavioral
Lead sponsor
Benten Technologies, Inc.
Industry
Eligibility
18 Years to 44 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Hyattsville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 4:21 PM EDT
Completed Phase 3 Interventional

Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer

NCT00003674
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Veno-occlusive Disease
Interventions
dalteparin, standard therapy
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
19
States / cities
Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 19, 2026, 4:21 PM EDT
Recruiting Not applicable Interventional

Clinical Utility of Residual Hearing in the Cochlear Implant Ear

NCT04707885
View directory record Official record
Conditions
Hearing Loss, Sensorineural, Hearing Loss, Hearing Loss, Bilateral
Interventions
Electrocochleography
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 79 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Rochester, Minnesota • St Louis, Missouri • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 19, 2026, 4:21 PM EDT